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Prostate-specific antigen (PSA) is a serine protease secreted at low levels by normal luminal epithelial cells of the prostate and in
significantly higher levels by prostate cancer cells. Therefore, PSA is a potential target for various immunotherapeutical approaches
against prostate cancer. DNA vaccination has been investigated as immunotherapy for infectious diseases in patients and for specific
treatment of cancer in certain animal models. In animal studies, we have demonstrated that vaccination with plasmid vector pVAX/
PSA results in PSA-specific cellular response and protection against tumour challenge. The purpose of the trial was to evaluate the
safety, feasibility and biological efficacy of pVAX/PSA vaccine in the clinic. A phase I trial of pVAX/PSA, together with cytokine
granulocyte/macrophage-colony stimulating factor (GM-CSF) (Molgramostim) and IL-2 (Aldesleukin) as vaccine adjuvants, was
carried out in patients with hormone-refractory prostate cancer. To evaluate the biologically active dose, the vaccine was
administered during five cycles in doses of 100, 300 and 900mg, with three patients in each cohort. Eight patients were evaluable. A
PSA-specific cellular immune response, measured by IFN-g production against recombinant PSA protein, and a rise in anti-PSA IgG
were detected in two of three patients after vaccination in the highest dose cohort. A decrease in the slope of PSA was observed in
the two patients exhibiting IFN-g production to PSA. No adverse effects (WHO grade 42) were observed in any dose cohort. We
demonstrate that DNA vaccination with a PSA-coding plasmid vector, given with GM-CSF and IL-2 to patients with prostate cancer,
is safe and in doses of 900mg the vaccine can induce cellular and humoral immune responses against PSA protein.
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Prostate cancer is the second most commonly diagnosed cancer
and the fourth leading cause of cancer-related death in men in the
developed countries worldwide (GLOBOCAN 2000, 2001). Effective
curative treatment modalities are debilitating, and are only
currently available for localised disease. In hormone-refractory
prostate cancer, no agent has been shown to prolong survival
beyond approximately 1 year. Tumour immunology is entering a
new era due to the advances in our understanding of the immune
network, and the identification of tumour antigens that can be
targeted by therapeutic manipulation of the immune system. With
regard to immunotherapy of prostate cancer, several prostatic
tissue-confined antigens have been described, such as prostate-
specific antigen (PSA), prostate-specific membrane antigen
(PSMA), prostate acid phosphatase (PAP) and prostate secretory
protein-94 (PSP94).
Prostate-specific antigen is a serine protease of the human
glandular kallikrein family restricted to higher primates (Riegman
et al, 1989). It is widely used in the early diagnosis and monitoring
of prostate cancer (Catalona et al, 1991). The gene encoding the
PSA protein is located on chromosome 19. Its androgen-regulated
transcription results in the biosynthesis of a 261 amino-acid PSA
precursor. By proteolytic cleavage, a 237 single chain form is
secreted into the seminal fluid by the columnar epithelial cells. The
PSA levels in seminal fluid are one million-fold higher than in
serum. Normal PSA levels in the serum in males are below
4ngml
 1. Far lower PSA expression has also been reported in
other tissues, among others the female breast (Diamandis and Yu,
1995).
Different formulations of PSA have been used in several early
clinical trials, demonstrating the possibility to induce immune
responses against a self-antigen, such as PSA, using active
immunisation. PSA has been formulated as recombinant protein
in liposomes (Meidenbauer et al, 2000), in recombinant vaccinia
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lvirus (Eder et al, 2000), as mRNA in autologous DC (Heiser et al,
2002) or HLA-A24-associated peptides (Noguchi et al, 2003).
DNA vaccines represent the latest development in vaccination
strategies (Ulmer et al, 1993). Direct introduction of plasmid DNA
into the cells of living hosts (by gene gun, or needle injection) leads
to the generation of both humoral and cellular immune responses
and protective immunity. Some of the advantages of DNA
vaccination are: specificity, nonimmunogenicity of the vector,
mammalian post-translational modification, stability, safety, cost
advantage and generic manufacturing. A serious disadvantage is
the relatively poor immune response induced with plasmid DNA as
compared to traditional vaccines (Liu, 2003) and therefore
combinations with various adjuvants are currently tested. Based
on published studies showing enhancement of DNA vaccines using
interleukin-2 (IL-2) and granulocyte/macrophage-colony stimulat-
ing factor (GM-CSF) (Mincheff et al, 2000; Parmiani et al, 2000),
and our preclinical results (unpublished), these two cytokines were
chosen as adjuvants.
Clinical trials demonstrated that DNA vaccines coding for viral
antigens induce significant levels of protein production (Liu,
2003), and evoke CD4
þ, CD8
þ and antibody responses in non-
cancer-bearing subjects. It is important to realise, however, that
immune responses to microbial vaccines in healthy individuals are
not comparable to immune responses to cancer vaccines in cancer
patients (Velders et al, 1998). At present, little is known as to how
the host-antigenic tolerance to tumour antigens in patients with
active cancer interferes with DNA-vaccine-induced responses. In
this respect, studies in animal models have severe limitations in
reflecting the clinical situation (Lollini and Forni, 2002). The few
published trials with DNA cancer vaccines give contradictory
results (Timmerman et al, 2002; Rosenberg et al, 2003; Tagawa
et al, 2003).
Since a naked DNA-vaccine coding for PSA has not been
previously tested in humans, we performed a phase I trial to
evaluate its adverse effects and determine the possible induction of
PSA-specific immune response.
MATERIALS AND METHODS
Study rational and objectives
The aim of this phase I trial was to evaluate the safety and
feasibility, and to determine the biologically effective dose of a
DNA vaccine.
Patient eligibility
The trial was approved by the Institutional Ethics Committee in
accordance with the principles of the Declaration of Helsinki and
the Swedish Medical Product Agency.
Nine patients with advanced prostatic adenocarcinoma were
enrolled after informed, signed consent into the trial. Patients were
diagnosed by fine-needle aspiration cytology and in one patient
the diagnosis was obtained using core-biopsy. The cytology
specimens were graded according to a three-tier system. The
core-biopsy was reviewed and graded according to the Gleason
system. Patients were required to have evidence of progressive
disease determined by either new bone or soft tissue lesions or
rising PSA level on three consecutive occasions despite androgen
deprivation (and if applicable, antiandrogen withdrawal). Patients
had to have the Eastern Cooperative Oncology Group performance
status of 2 or less with an estimated life expectancy of at least 6
months. They were assessed as unlikely to require chemotherapy,
radiation therapy or administration of corticosteroids (corre-
sponding to 4400mgday
 1 of Bunesonide) for at least 6 months.
Exclusion criteria included manipulation of hormonal therapy,
radiation or chemotherapy within 10 weeks prior to inclusion,
clinical evidence of central nervous system (CNS) metastases,
active condition of allergy or autoimmune disease, noncutaneous
malignant process, current or history of immunodeficiency,
including previous splenectomy or irradiation of the spleen.
Study design
pVAX/PSA was given at three dose levels with three patients at
each level (Figure 1). The levels were determined arbitrarily by
multiplying the dose by 3 as follows: 100mg given 90mg
intramuscularly (i.m.) þ 10mg intradermally (i.d.); 300mg  
(270mg i.m. þ 30mg i.d.) and 900mg   (810mg i.m. þ 90mg i.d.).
Vaccine was administered in the deltoid region for a total of five
times at 4-week interval. To optimise vaccination, the following
cytokines were given concomitantly as vaccine adjuvants: GM-CSF
(Molgramostim, Leucomax
s, Schering-Plough & Novartis, Swe-
den) (40mgday
 1  3 days starting 2 days before vaccination)
subcutaneously (s.c.) at the same site as vaccination, and IL-2
(Aldesleukin, Proleukin
s, Chiron, Holland) (75mgday
 1  7 days
starting the day after vaccination) s.c. in the same extremity.
No chemotherapy, radiation therapy, corticosteroids (corre-
sponding to 4400mgday
 1 of Bunesonide) or manipulation of
anti-androgen suppression were allowed during the study.
All patients were evaluated for toxicity by the National Cancer
Institute of Canada Clinical Trials Group (NCIC-CTG). Patients
were enrolled in the higher dose cohort if dose-limiting toxicity
X3 was not reached.
Vaccine (pVAX/PSA)
The vaccine was produced from a gene coding for the full-length
human PSA protein (Lundwall and Lilja, 1987), obtained from Dr
Tim, Ratliff, Washington University, St Louis, USA. It was inserted
into the pVAX1 vector (Invitrogen, The Netherlands), a plasmid
fulfilling the Food and Drug Administration, Center for Biologics
Evaluation and Research (FDA CBER) regulations for vectors to be
used in human DNA vaccination protocols. Sequence analysis
revealed a single nucleotide difference of A to C at the position 289
compared with the published sequence (NM_001648).
The vaccine was produced by the ‘Gene Therapy Center’ at
Huddinge Hospital, Stockholm, under Good Manufacturing
Practice (GMP) conditions with endotoxin content p10EUmg
 1,
485% supercoiled, protein content o10mgmg
 1 of plasmid and
chromosomal DNA content o30mgmg
 1 of plasmid. The vaccine
was aliquoted in saline solution, stored at  801C and thawed just
prior to administration. All handling of the DNA vaccine was per-
formed according to NIH Guidelines for research involving recom-
binant DNA molecules. The PSA protein expression was verified
by transfection into Cos7 cells and after i.m. injection in mice.
Evaluation of immune response
Patient blood and serum were collected in heparinised containers
and glass tubes, respectively, before the study, and 4 weeks after
second and fifth vaccinations (Figure 1). Peripheral blood mono-
nuclear cells (PBMC) were isolated by Ficoll density separation
(Pharmacia, Uppsala, Sweden), resuspended in 90% autologous
plasma and 10% DMSO, aliquoted and cryopreserved in liquid
nitrogen until in vitro analysis. Patient serum was cryopreserved at
 801C until analysis.
Cellular response Thawed PBMC were plated at 5 10
6ml
 1 in
24-well plates and incubated for 2h. Adherent cells were
differentiated in X-vivo 15 medium with 2% autologous plasma
supplemented with interleukin-4 (IL-4) (40ngml
 1) (Schering-
Plough, Kenilworth, NJ, USA) and GM-CSF (50ngml
 1) (Schering-
Plough & Novartis, Sweden). Immature dendritic cells (DC) were
harvested on day 6 and loaded with recombinant PSA protein
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l(Novavax Inc., Rockville, MD, USA). Briefly, Lipofectin (10mg)
(Invitrogen, Carlsbad, CA, USA) and recombinant PSA (5mg) were
mixed for 20min at 201C and thereafter added to DC in a total
volume of 200ml X-vivo 15 medium and incubated for 4h. DC were
washed three times in PBS and treated with TNFa (50ngml
 1)
(Chiron, Emmeryville, CA, USA) for an additional 48h to allow
maturation.
For stimulation, nonadherent cells, obtained from a second
PBMC aliquot, were cultured with autologous PSA-transfected DC
at a responder stimulator ratio of 10:1 in X-vivo 15 supplemented
with 2% autologous plasma, IL-7 (20ngml
 1) and IL-12
(100pgml
 1) (both R&D Systems Inc., Minneapolis, MN, USA)
for 7 days. On day 8, responder cells were harvested, restimulated
and resuspended in X-vivo 15 with 2% autologous plasma. At 2
days after restimulation, on day 10, IL-2 (R&D systems Inc.) was
added to the culture at 20Uml
 1. On day 16 of culture, responder
cells were harvested and analysed in duplicates for IFNg
production after 48h coculture with PSA or human serum
albumin- (HSA) (Pharmacia) loaded autologous DC (IFN-g ELISA,
Mabtech AB, Stockholm, Sweden). No other cytokines were tested.
Antibody response Patient serum samples, collected before first
vaccination and after five cycles of vaccinations, were analysed in
parallel by ELISA for reactivity against recombinant PSA protein.
Plates (96 well) were coated overnight at þ41C with human
recombinant PSA protein at 2mgml
 1 in carbonate–bicarbonate
buffer (pH 9.5). After blocking with PBS containing 0.05% Tween
20 and 0.25% bovine serum albumin (BSA), pH 7.4 (blocking
buffer), serial dilutions of patient serum in blocking buffer were
incubated for 4h at room temperature. Secondary antibody
peroxidase-labelled goat anti-human IgG (Southern Biotechnology
Associated, Birmingham, AL, USA) was added. Assay was
developed using DAKO TMB one-step substrate system (DAKO,
Carpinteria, CA, USA) and measured spectrophotometrically at
450nm. Samples were analysed in duplicate.
Clinical monitoring
Each patient had a chest radiograph, bone scan and abdominal
computer-assisted tomography (CAT) scan or magnetic resonance
imaging (MRI), on entry and on week 20 (4 weeks after the fifth
vaccination). Standard laboratory tests, before each vaccination
cycle and 4 weeks after the last one, included: blood count,
sedimentation rate, liver enzymes, creatinine, coagulation status,
antinuclear and antimuscular antibodies, rheumatoid factor and
PSA. PSA levels in patient plasma were measured using
PROSTATUSt, fluoroimmunoassay (Wallac Oy, Turku, Finland)
at the Department of Clinical Biochemistry, Karolinska Hospital.
Patients were followed for minimum 16 weeks after the fifth
vaccination or until inclusion in another study protocol.
RESULTS
Patient characteristics and treatment
Between August 2000 and January 2002, nine patients with
histologically proven, PSA-positive, hormone-refractory prostate
cancer were enrolled in this study. Their detailed characteristics
are described in Table 1. None of the patients received previous
chemotherapy. Five had measurable metastasis and the other four
had prostate cancer evaluable by increase in serum PSA. The study
comprised five cycles of pVAX/PSA DNA vaccination in combina-
tion with recombinant GM-CSF and IL-2 protein administered as
adjuvant (Figure 1). This adjuvant combination appeared bene-
ficial compared to no adjuvant or either cytokine alone in a
Table 1 Characteristics of patients enrolled, including doses and adverse toxicities observed
Patient # Age (years)
Tumour
grade
a
Years since
diagnosis
Months on
hormonal
therapy ECOG status
Baseline PSA
(ngml
 1)
Metastatic
site
pVAX/PSA
dose (lg)
Adverse
effects
b
WHO grade
1 64 2 7.4 20 0 15 None 100 2
2 80 3 6.8 45 1 39 Bone/lung 100 1
3 76 3 9.1 23 0 15 Bone 100 1
4 74 2 8.8 44 1 3.1 Bone/lung 300 1
5 71 2 6.3 68 0 15 Bone 300 1
6 68 Gleason score
4+4
9.5 10 0 9.2 Lymph node 300 Not evaluable
c
7 68 2 3.3 40 0 11 None 900 1
8 78 2 5.5 13 1 9.2 None 900 1
9 62 2 10.0 48 1 3.6 None 900 2
ECOG¼Eastern Cooperative Oncology Group; WHO¼World Health Organization.
aPatients were diagnosed by fine-needle aspiration cytology and graded according to a
three-tier system. In patient #6, the diagnosis was obtained using core-biopsy, reviewed and graded according to the Gleason system.
bMost common adverse toxicities were:
systemic (reported in six patients) such as running nose, fatigue, myalgia, chills, and fever; and local at injection site (reported in seven patients) such as erythaema, swelling,
induration, itching, local pain and papular urticaria.
cPatient developed upper urinary obstruction 1 week after first vaccination and was removed from study. This event was not
related to investigational therapy.
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Figure 1 Flow chart of clinical study. Vaccine (pVAX/PSA) was
administered in doses 100, 300 and 900mg (90% i.m. and 10% i.d.).
Recombinant GM-CSF and IL-2 were administered s.c.
Plasmid DNA vaccine with PSA in prostate cancer
M Pavlenko et al
690
British Journal of Cancer (2004) 91(4), 688–694 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lpreclinical tumor-protection study (Roos et al (in press)). All
patients had rising PSA on three consecutive occasions with on-
study range between 3.1 and 39mgl
 1. Their concurrent androgen-
withdrawal therapy medication was not manipulated for 10 weeks
before or during the study.
The dosage of the vaccine (100, 300 and 900mg) was determined
arbitrarily; starting with the dose used in our preclinical toxicology
studies submitted to the regulatory authorities (100mg). A
threshold dose required to obtain significant responses was
described at the time of initiation of the trial with malaria DNA
vaccine in healthy volunteers and therefore the maximum dose was
set at 900mg (Wang et al, 1998). The cytokine dose was kept
constant in all cohorts in order to rule out the nonspecific
stimulatory effect of the adjuvants.
Eight patients completed all five vaccination cycles and were
fully evaluable for analysis. Patient #6 required withdrawal from
study 1 week after the first vaccine administration due to bilateral
upper urinary obstruction and hydronephrosis. This event was
unrelated to the vaccination.
Safety
The drug tested is not a cytotoxic agent, and therefore the study
was not designed to determine the maximum tolerated dose
(MTD), but to evaluate the safety and feasibility and to determine
the biologically effective dose. No dose-limiting toxicity (DLT)
occurred at any dose level tested. The vaccine-related toxicities are
shown in Table 1. Neither the frequency nor the severity of adverse
toxicities was associated with the administered dose of the vaccine.
Treatment-related side effects did not exceed WHO grade 2. They
were systemic, such as running nose, fatigue, myalgia, chills and
fever (n¼6), and at the injection site: erythaema, swelling,
induration, itching, local pain and papular urticaria (n¼7). Two
patients, one receiving the lowest and one the highest vaccine dose
developed the highest WHO grade 2 local reactions. The adverse
toxicities at the injection site developed in association with
administration of GM-CSF prior to pVAX/PSA administration. The
systemic toxicities appeared several days post pVAX/PSA injec-
tion, during IL-2 administration. All adverse effects were self-
limited within 2–3 days after the last IL-2 injection.
No significant changes occurred in the monitored serological
parameters, except for minor elevation of antinuclear antibodies.
The titre did not exceed 1:100. None of the patients developed
clinically evident autoimmune disease.
Responses
A secondary objective of this study was to determine immunolo-
gical consequences of pVAX/PSA vaccination. For this reason,
PBMC and serum samples were collected before the study, before
the third vaccination and 4 weeks after the last vaccination
(Figure 1). All cell and serum samples were frozen and stored at
 180 and  801C, respectively, until analysis. To minimise bias due
to interassay variability, the analyses were performed simulta-
neously for all samples from each patient. The sample identity was
blinded for evaluation. This approach did not influence the
conduct of the trial, since the immunological efficacy of the
vaccine was not critical for the continuation of the study.
PSA-specific cellular immune response The cellular immune
responses were assessed against the whole recombinant PSA
protein for the following reasons: (1) this approach enables
detection of immune responses elicited by both CD4þ and CD8þ
T cells; (2) it prevents false-positive nonspecific reactivity against
contaminants in the vaccine formulation and (3) in the published
PSA vaccine trials (Meidenbauer et al, 2000; Heiser et al, 2002),
immune responses were also monitored against full-length PSA
protein thus enabling comparison.
In order to demonstrate PSA specificity of IFN-g production, the
nonspecific response against HSA was assayed in parallel for each
sample
No patient mounted a detectable PSA-specific IFN-g response
prior to vaccination (Figure 2). Undetectable PSA-specific IFN-g
response was also present after vaccination in patient groups that
received pVAX/PSA in the low and intermediate doses of 100 and
300mg (Figure 2A and B). Two of three patients that received the
highest DNA vaccine dose (900mg) had a significant increase in
IFN-g response. In patient #8, the increase was not significant.
Patient #7 had no detectable response after the second vaccination
cycle (data not shown). The sample after the fifth vaccination is
not available from patient #9 (Figure 2C).
PSA-specific antibody response Patient sera were also assessed for
PSA-specific IgG levels before and after vaccination. While a PSA-
specific cellular response was below detection limit in all patients
prior to vaccination, certain patients exhibited low levels of PSA-
reactive antibodies (Abs) at enrolment (Figure 3). One exception
was patient #9 who already had a significant anti-PSA level on
presentation. In the low and intermediate dose group, no
conclusive induction of PSA-specific Abs was detected (Figure
Pat.#8
−0.3
0.0
0.3
0.6
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Figure 2 Induction of T-cell response to recombinant PSA, prior to and
postvaccination, measured as IFN-g production by ELISA after restimulation
with DC loaded with PSA protein. Nonspecific reactivity against a control
protein (HSA) has been subtracted from each individual sample. Patient
groups vaccinated per cycle with 100mg (Pat#1–3), 300mg (Pat#4–6) and
900mg (Pat#7–9) of pVAX/PSA are shown in panels (A, B and C),
respectively. Prior and post study values are presented if otherwise not
stated. Bars represent mean values of two individual experiments with
standard deviations.
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developed a significant increase in anti-PSA Abs (Figure 3C). In
patient #9, it remained an unchanged high, as compared to the
prevaccination level.
Clinical consequences The main objectives of this trial were to
assess the feasibility, safety and immunogenicity of the DNA
vaccine. Nevertheless, all enrolled patients were also considered for
evidence of clinical responses. Patients #5, #7 and #9 developed an
objective decrease in the slope of their PSA levels (Figure 4B and
C). All other patients (n¼5) exhibited a biochemical progression
with regard to their serum PSA levels (Figure 4). Four patients with
evaluable metastasis on enrolment exhibited radiologically stable
disease (no change in tumour volume). Patient #2 exhibited an
objective progression of his bone metastasis as documented by the
postvaccination bone scan. Patient #8 developed liver metastasis as
determined by postvaccination CAT scan. Both of these events are
a natural disease progression in this group of patients.
In conclusion, in this trial, a dose–response was observed with
regard to induction of a PSA-specific immune response. The two
patients that developed cellular immune response to PSA protein
exhibited stabilisation of disease. In contrast, only one of six that
did not develop PSA-reactivity showed clinical stabilisation. To
demonstrate a significant antitumoral activity, a phase II trial
needs to be performed at the highest dose of vaccine.
DISCUSSION
This first clinical trial of a plasmid DNA vaccine encoding PSA was
designed to evaluate the feasibility, safety and immunogenicity of
pVAX/PSA in patients with prostate cancer. The novel finding of
this trial is that this DNA/PSA vaccine, given together with GM-
CSF and IL-2 to patients with prostate cancer, is safe and in doses
of 900mg can induce PSA-specific immunity. As might have been
expected from other clinical trials using DNA vaccines against
human immunodeficiency virus (HIV), malaria, melanoma or B-
cell lymphoma, only self-limiting adverse toxicities were observed
with this pVAX/PSA vaccine (Calarota et al, 1998; MacGregor et al,
1998; Le et al, 2000; Timmerman et al, 2002; Rosenberg et al, 2003;
Tagawa et al, 2003). The adverse toxicities observed in the trial
were not associated with the dose of the vaccine administered, but
time wise correlated with the administration of the two cytokines
that were used as adjuvants.
The dose–response observed in this trial, with respect to the
biologically effective dose, is in line with other trials with DNA
vaccine and other antigens, in which a certain threshold was
required to induce significant responses with DNA vaccination
(Wang et al, 1998; Timmerman et al, 2002). Since there were no
PSA-specific responses detected with the two lower DNA doses,
the nonspecific enhancement of the immune status due to the
administration of GM-CSF and IL-2 is unlikely. We are of the
opinion that this effect is due to the increased amount of PSA
protein produced. Nevertheless, it cannot be excluded that the
higher doses of plasmid DNA itself might have functioned as
immunological adjuvant. It is well established that bacterial DNA
sequences, by virtue of different methylation pattern from
mammalian DNA, may activate the immune system (Sato et al,
1996; Klinman et al, 1997).
It is interesting to note that a similar dose response was recently
reported in rhesus macaques immunised with a similar DNA
vaccine coding for human PSA (Kim et al, 2001). In this study,
Kim et al observed PSA-specific induction of IFN-g in animals that
received 500mg or more of plasmid DNA. Our study extends these
findings, demonstrating immune responses in patients exhibiting
all impediments to immunotherapy associated with advanced
stages of cancer and despite of the presence of large quantities of
circulating self-antigen. Nevertheless, in stage IV melanoma
patients vaccinated with 1mg doses of plasmid DNA encoding
gp100, Rosenberg et al (2003) have not detected any immune
responses. The conclusions of this trial are uncertain as only five of
the 22 enrolled patients completed the intended four cycles of
vaccination, while others were taken off protocol after one or two
cycles due to tumour progression.
The immunological monitoring is an important surrogate
marker of all early-stage cancer vaccine trials, since other end
points, such as patient survival in this advanced group of patients,
are not indicative of vaccine potency. Nevertheless, the choice of
the different monitoring tools is a matter of constant debate
(Keilholz et al, 2002; Coulie and van der Bruggen, 2003). Although
HLA A2-restricted PSA-derived peptides have been identified
(Correale et al, 1997; Chakraborty et al, 2003), the use of peptides
for immunological monitoring significantly limits the number of
evaluable patients, when whole antigen vaccines are used. This was
recently documented by Gulley et al (2002) in a trial with a
recombinant vaccinia vector encoding PSA, where only five of the
42 enrolled patients could be immunologically tested.
Read-outs in this study were measured against recombinant PSA
protein, to avoid nonspecific reactivity against contaminants in the
vaccine formulation. By comparing the PSA-specific responses
before and after vaccination, clonal amplification could be detected
both in the T- and B-cell response. It is most unlikely, however,
that the PSA-specific antibody responses are of clinical benefit,
since PSA is a secreted antigen and thus this read-out serves
merely as a marker of the effective delivery of the vaccine. It is
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Figure 3 Induction of IgG antibody against recombinant PSA in serum
measured at 1:100 dilution by ELISA prior to and post five cycles of
vaccination. Patient groups vaccinated per cycle with 100mg (Pat#1–3),
300mg (Pat#4–6) and 900mg (Pat#7–9) of pVAX/PSA are shown in
panels (A, B and C), respectively. Bars represent mean of duplicates with
standard deviations.
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ltherefore intriguing to note that antibody titres were highest after
the vaccination in all three patients receiving 900mg doses, while
only in one patient in the other two dosage cohorts. Furthermore,
the T-cell response was enhanced in two of these patients.
The design of this study does not allow us to assess the value of
the addition of GM-CSF and IL-2 as vaccine adjuvants nor the
optimal vaccine dose or route of administration for induction of
PSA-specific immune responses. The GM-CSF dose of 40mg was,
per vaccination cycle, 30-fold lower compared to the dose of GM-
CSF (Sangramostim) that modulated PSA kinetics when given as a
single agent (Rini et al, 2003). The reduction in the slope of PSA
increase observed in the two patients mounting cellular PSA
responses is thus unlikely to be a GM-CSF effect. Antitumoral
effects of IL-2 are limited in prostate cancer and otherwise only
reported at higher treatment doses (Freedland et al, 2001)
Taken together, our study demonstrates the safety of a plasmid
DNA vaccine encoding PSA, and that in doses of 900mg the vaccine
can induce cellular and humoral immune responses against PSA
protein. The proof for clinical benefit needs to be established in
further trials. Nevertheless, these results provide the basis for
further clinical development directed towards improving plasmid
DNA vaccination procedures against solid tumours, which may
lead to more potent and durable immunotherapeutical responses.
The identification of the patient groups most likely to benefit from
this immunotherapeutic treatment strategy provides a further
challenge in future studies.
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time of individual DNA vaccine administration.
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